Torsemide as a Primary Choice in Edema Associated with Heart Failure.

Akshyaya Pradhan, Amarnath Sugumaran, Rahul Patil, Mangesh Tiwaskar, Febin Francis, Janakiraman Ezhilan, Sunil Dighe, Chetan Shah, Vikas Chopra, Prabin Srivastava, Asha Mahilmaran, Suzaur Rahman, Amit Malviya, Anshuman Gupta, Phani Teja

Journal: The Journal of the Association of Physicians of India 2024;72(9S):19-23

PMID: 39291568

View on PubMed

Abstract

Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action. If an oral dose had not been provided, intravenous (IV) administration of torsemide, or equal doses of furosemide and bumetanide, was preferred. However, the key variables for selecting and administering loop diuretics are their pharmacological qualities as well as their clinical efficacy. Torsemide has greater bioavailability, a higher rate of absorption, a longer duration of action, and lesser ototoxicity, making it the primary choice in the management of edematous HF.

Address: Head, Department of Peripheral and Vascular, The Madras Medical Mission Hospital, Chennai, Tamil Nadu, India, Corresponding Author.; Interventional Cardiologist, Department of Cardiology, Medicover Hospital, Sangamner, Mumbai, Maharashtra, India.; Senior Consultant Cardiologist and Head, Department of Cardiology, Zynova Shalby Hospital, Mumbai, Maharashtra, India.; Consultant Physician and Diabetologist, Department of Medicine, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.; Director, Department of Interventional Cardiology, Primus Super Speciality Hospital, Delhi, India.; Consultant Interventional Cardiologist, Department of Cardiology, Ruby Hall Clinic, Pune, Maharashtra, India.; Senior Interventional Cardiologist, Department of Cardiology, RIMS Hospital, Ranchi, Jharkhand, India.; Professor, Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.; Consultant Interventional Cardiologist, Department of Cardiology, Medica Superspecialty Hospital, Kolkata, West Bengal, India.; Professor, Department of Cardiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.; Interventional Cardiologist and Assistant Professor, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.; Consultant Cardiologist, Department of Cardiology, KIMS Hospital, Rajahmundry, Andhra Pradesh, India.; Medical Advisor, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.; Cluster Medical Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.

DOI: 10.59556/japi.72.0672

Link outs

Free resources

Medical:

https://medlineplus.gov/heartfailure.html

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-2658

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-GZMA-1

MeSH Terms: Humans, Heart Failure, Torsemide, Edema, Sodium Potassium Chloride Symporter Inhibitors, Diuretics